Iron: A target for the management of Kaposi's sarcoma?

BMC Cancer

Volumn 4, Issue , 2004, Pages

  Simonart, Thierry ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; BLEOMYCIN; CARCINOGEN; CISPLATIN; CP 502; DEFERASIROX; DEFERIPRONE; DEFERITRIN; DEFEROXAMINE; ENZYME INHIBITOR; ERYTHROPOIETIN; IRON; IRON CHELATING AGENT; MPB 0201; PYRIDOXAL ISONICOTINOYLHYDRAZONE; RIBONUCLEOTIDE REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; PYRIDONE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; DRUG TARGETING; HUMAN; IRON CHELATION; KAPOSI SARCOMA; NONHUMAN; SARCOMA CELL; AFRICA; FEMALE; HUMAN HERPESVIRUS 8; IRON OVERLOAD; MALE; TOPOGRAPHY; VIROLOGY;

AFRICA; DEFEROXAMINE; FEMALE; HERPESVIRUS 8, HUMAN; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PYRIDONES; SARCOMA, KAPOSI; TOPOGRAPHY, MEDICAL;

EID: 3042836376     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-4-1     Document Type: Article

References (57)

1. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266:1865-1869.
2. Noel JC, Hermans P, Andre J, Fayt I, Simonart T, Verhest A, Haot J, Burny A: Herpesvirus-like DNA sequences and Kaposi's sarcoma. Relationship with epidemiology, clinical spectrum, and histologic features. Cancer 1996, 77:2132-2136.
3. Antman K, Chang Y: Kaposi's sarcoma. N Engl J Med 2000, 342:1027-1038.
4. Staskus KA, Zhong K, Bebhard B, Herndier B, Wang H, Renne R, Beneke J, Pudney J, Anderson DJ, Ganem D, Haase AT: Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 1997, 71:715-719.
5. Boschoff C, Schulz TF, Kennedy MM, Graham AK, Fisher C, Thomas A, McGee JO, Weiss RA, O'Leary JJ: Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cell. Nature Med 1995, 1:1274-1278.
6. Schulz TF, Sheldon J, Greensill J: Kaposi's sarcoma-associated herpesvirus (KSHV) or human herpesvirus 8 (HHV8). Virus Res 2002, 82:115-126.
7. Lenette ET, Blackbourn DJ, Levy JA: Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 1996, 348:858-861.
8. Chatlynne L, Ablashi D: Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV). Semin Cancer Biol 1999, 9:175-185.
9. Gallo RC: The enigmas of Kaposi's sarcoma. Science 1998, 282:1837-1839.
10. Dedicoat M, Newton R: Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. Br J Cancer 2003, 88:1-3.
11. Biggar RJ, Whitby D, Marshall V, Linhares AC, Black F: Human herpesvirus 8 in Brazilian Amerindians: a hyperendemic population with a new subtype. J Infect Dis 2000, 181:1562-1568.
12. Taylor JF, Smith PG, Bull D, Pike MC: Kaposi's sarcoma in Uganda: geographic and ethnic distribution. Br J Cancer 1973, 26:483-495.
13. Cook-Mozaffari P, Newton R, Beral V, Bukitt DP: The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer 1998, 78:1521-1528.
14. Ziegler JL: Endemic Kaposi's sarcoma in Africa and local volcanic soils. Lancet 1993, 342:1348-1351.
15. Ziegler JL, Newton R, Katongole-Mbidde E, Mbulataiye S, De Cock K, Wabinga H, Mugerwa J, Katabira E, Jaffe H, Parkin DM, Reeves G, Weiss R, Beral V: Risk factors of Kaposi's sarcoma in HIV-positive subjects in Uganda. AIDS 1997, 11:1619-1626.
16. Ziegler JL, Newton R, Bourboulia D, Casabonne D, Beral V, Mbidde E, Carpenter L, Reeves G, Parkin DM, Wabinga H, Mbulaiteye S, Jaffe H, Weiss R, Boshoff C: Risk factors for Kaposi's sarcoma: a case-control study of HIV-seronegative people in Uganda. Int J Cancer 2003, 103:233-240.
17. Price EW: Podoconiosis. Non-filarial elephantiasis. Oxford: Oxford University Press 1990.
18. Simonart T, De Dobbeleer G, Stallenberg B: Kaposi's sarcoma in a metallurgist: role of iron filings? Br J Dermatol 2003, 148:1061-1063.
19. Montella M, Franceschi S, Geddes M, Arniani S, Cocchiarella G: Classic Kaposi's sarcoma and volcanic soil in southern Italy. Lancet 1996, 347:905.
20. Krauskopf KB: Introduction to Geochemistry McGraw-Hill, Kogahusha Ltd: London; 1979.
21. Hjalgrim H, Tulinius H, Dalberg J, Hardarson S, Frisch M, Melbye M: High incidence of classical Kaposi's sarcoma in Iceland and the Faroe Islands. Br J Cancer 1998, 77:1190-1193.
22. Ollier C: Weathering Longman Group Ltd: Essex; 1984.
23. Weinberg ED: The role of iron in cancer. Eur J Cancer Prev 1996, 5:19-36.
24. Ludin PM: The carcinogenic action of complex iron preparations. Br J Cancer 1961, 15:838-847.
25. Dreyfus JR: Lungencarcinoma bei Geschwisteern nach Inhalation von eisenoxydaltigem Staub in der Jugend. Zeit Klin Med 1936, 130:256-260.
26. Sherson D, Svane O, Lynge E: Cancer incidence among foundry workers in Denmark. Arch Environ Health 1991, 46:75-81.
27. Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, Fraumeni JF Jr: Cancer risk following primary haemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995, 60:160-162.
28. Knekt P, Reuanen A, Takkunen H, Aromaa A, Heliovaara M, Hakulinen T: Body iron stores and risk of cancer. Int J Cancer 1994, 56:379-382.
29. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS: Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994, 56:364-369.
30. Cazzola M, Bergamaschi G, Dezza L, Arosio P: Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation. Blood 1990, 75:1903-1919.
31. Reichard P, Ehrenberg A: Ribonucleotide reductase: A radical enzyme. Science 1983, 221:514-519.
32. Boelaert JR, Weinberg GA, Weinberg ED: Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect Agents Dis 1996, 5:36-46.
33. Simonart T, Noel JC, Andrei G, Parent D, Van Vooren JP, Hermans P, Lunardi-Yskandar Y, Lambert C, Dieye T, Farber CM, Liesnard C, Snoeck R, Heenen M, Boelaert JR: Iron as a potential cofactor in the pathogenesis of Kaposi's sarcoma. Int J Cancer 1998, 78:720-726.
34. Simonart T, Degraef C, Stordeur P, Noel JC, Mosselmans R, Van Vooren JP, Parent D, Boelaert JR, Heenen M, Galand P: Iron induces bcl-2 expression in human dermal microvascular endothelial cells. Free Rad Res 2001, 34:221-235.
35. Lunardi-Iskandar Y, Bryant JL, Zeman RA, Lam VH, Samaniego F, Besnier JM, Hermans P, Thierry AR, Gill P, Gallo RC: Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 1995, 375:64-68.
36. Oettle AG: Geographical and racial differences in the frequency of Kaposi's sarcoma as evidence of environmental or genetic causes. Acta Un Int Cancr 1962, 18:330-363.
37. Gordeuk VR, Boyd RD, Brittenham GM: Dietary iron overload persists in rural sub-Saharan Africa. Lancet 1986, 1:1310-1313.
38. Weinberg ED: Development of clinical methods of iron deprivation for suppression of neoplastic and infectious diseases. Cancer Invest 1999, 17:507-513.
39. Gao J, Richardson DS: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood 2001, 98:842-850.
40. Simonart T, Degraef C, Andrei G, Mosselmans R, Hermans P, Van Vooren JP, Noel JC, Boelaert JR, Snoeck R, Heenen M: Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J Invest Dermatol 2000, 115:893-900.
41. Simonart T: Inhibition of vascular cell adhesion molecule-1 expression in human dermal microvascular endothelial cells by iron chelators. J Invest Dermatol 2003, 121:1129-30.
42. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J, Carrascal T, Walsh P: IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 2000, 97:734-739.
43. Nakao S, Kuwano T, Ishibashi T, Kuwano M, Ono M: Synergistic effect of TNF-alpha in soluble VCAM-1-induced angiogenesis through alpha(4) integrins. J Immunol 2003, 170:5704-5711.
44. Simonart T, Boelaert JR, Andrei G, van den Oord JJ, Degraef C, Hermans P, Noel JC, Van Vooren JP, Heenen M, De Clercq E, Snoeck R: Desferrioxamine enhances AIDS-associated Kaposi's sarcoma tumor development in a xenograft model. Int J Cancer 2002, 100:140-143.
45. Beerepoot LV, Shima DT, Kuroki M, Yeo KT, Voest EE: Up-regulation of vascular endothelial growth factor production by iron chelation. Cancer Res 1996, 56:3747-3751.
46. Meyer-Brunot HG, Keberle H: The metabolism of desferrioxamine B and ferrioxamine B. Biochem Pharmacol 1967, 16:527-535.
47. Lovejoy DB, Richardson DR: Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem 2003, 10:1035-1049.
48. Richardson DR, Milnes K: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1997, 89:3025-3038.
49. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R: Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003, 43:565-572.
50. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG: Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003, 361:1597-1602.
51. Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M: Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res 2003, 9:4092-4100.
52. Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V: Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 2003, 27:1077-83.
53. Tam TF, Leung-Toung R, Li W, Wang Y, Karimian K, Spino M: Iron chelator research: past, present, and future. Curr Med Chem 2003, 10:983-995.
54. Husain SR, Kreitman RJ, Pastan I, Puri RK: Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat Med 1999, 5:817-22.
55. Yang TY, Chen SC, Leach MW, Manfra D, Homey B, Wiekowski M, Sullivan L, Jenh CH, Narula SK, Chensue SW, Lira SA: Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 2000, 191:445-54.
56. Foreman KE, Friborg J, Chandran B, Katano H, Sata T, Mercader M, Nabel GJ, Nickoloff BJ: Injection of human herpesvirus-8 in human skin engrafted on SCID mice induces Kaposi's sarcoma-like lesions. J Dermatol Sci 2001, 26:182-93.
57. Bubman D, Cesarman E: Pathogenesis of Kaposi's sarcoma. Hematol Oncol Clin N Am 2003, 17:717-745.